Last reviewed · How we verify

NCT06266949

Perimetry Based on Eye-movements in Patients With (Supra)Sellar Tumors

Not yet recruiting Last updated 2 May 2025
What this trial tests

trial testing SONDA in Pituitary Tumor in 30 participants. Not yet recruiting.

Timeline
1 August 2025
Primary endpoint
1 April 2026
1 August 2026

Quick facts

Lead sponsorUniversity Medical Center Groningen
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment30
Start date1 August 2025
Primary completion1 April 2026
Estimated completion1 August 2026
Sites1 location across Netherlands

Drugs / interventions tested

Conditions studied

Sponsor

University Medical Center Groningen

Who can join

18 and older, any sex, with Pituitary Tumor or Visual Fields Hemianopsia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess wether the SONDA visual field test is suitable for patients with a supra sellar tumour.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pituitary Tumor

Currently open trials in the same condition.

Other University Medical Center Groningen trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06266949.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing